Quoin Pharmaceuticals Ltd ADR (QNRX)

Overview News Price History Discussions Forecast Stock Split

Quoin Pharmaceuticals Ltd ADR stock is currently priced at $0.66, with a 24-hour trading volume of 82,684. It has seen a +0.00% increased in the last 24 hours and a -21.43% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.6766 pivot point. If it approaches the $0.6134 support level, significant changes may occur.

Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Financials Data

Quoin Pharmaceuticals Ltd ADR (QNRX) Net Income 2024

QNRX net income (TTM) was -$8.69 million for the quarter ending December 31, 2023, a +7.41% increase year-over-year.

Quoin Pharmaceuticals Ltd ADR (QNRX) Cash Flow 2024

QNRX recorded a free cash flow (TTM) of -$7.86 million for the quarter ending December 31, 2023, a +9.92% increase year-over-year.

Quoin Pharmaceuticals Ltd ADR (QNRX) Earnings per Share 2024

QNRX earnings per share (TTM) was -$10.24 for the quarter ending December 31, 2023, a +87.99% growth year-over-year.

Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Latest News

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

Benzinga

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

GlobeNewswire Inc.

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

GlobeNewswire Inc.

Crude Oil Down 1%; Dave Shares Jump After Q4 Results

Benzinga

Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Nasdaq Down 250 Points; ISM Services PMI Falls In February

Benzinga

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.